The macrophage activation marker sCD163 combined with markers of the Enhanced Liver Fibrosis (ELF) score predicts clinically significant portal hypertension in patients with cirrhosis-Reference-Cited by-同舟云学术

The macrophage activation marker sCD163 combined with markers of the Enhanced Liver Fibrosis (ELF) score predicts clinically significant portal hypertension in patients with cirrhosis

Published:2016-04-07 Issue:11 Volume:43 Page:1222-1231
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Sandahl T. D.¹,McGrail R.²,Møller H. J.²,Reverter E.³,Møller S.⁴,Turon F.³,Hernández-Gea V.³,Bendtsen F.⁵,Vilstrup H.¹,Garcia-Pagan J. C.³,Grønbaek H.¹

Affiliation:

1. Department of Hepatology & Gastroenterology; Aarhus University Hospital; Aarhus Denmark

2. Department of Clinical Biochemistry; Aarhus University Hospital; Aarhus Denmark

3. Barcelona Hepatic Hemodynamic Laboratory; Liver Unit; Hospital Clinic; Institut de Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (Ciberehd); Barcelona Spain

4. Department of Clinical Physiology and Nuclear Medicine; 239 Center for Functional and Diagnostic Imaging and Research; Faculty of Health Sciences Hvidovre Hospital; University of Copenhagen; Hvidovre Denmark

5. Gastroenterology Unit; Medical Section; Hvidovre Hospital; University of Copenhagen; Hvidovre Denmark

Funder

Novo Nordisk UK Research Foundation

Lundbeckfonden

Savvaerksejer Jeppe Juhl og Hustru Ovita Juhls Mindelegat

Strategiske Forskningsråd

Ministerio de Ciencia e Innovación

Instituto de Salud Carlos III

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology